ConductScience.org, home

Paper19840887

Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study.

Fleming GF and 10 others. Gynecol Oncol, 2010. Cited by 213 papers, by iCite.

Cite this record

ConductScience Library. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. Papers, record 19840887. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19840887

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study.
PubMed
Journal
Gynecol Oncol
PubMed
Year
2010
PubMed
Publication types
Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
213
iCite
Relative citation ratio, by iCite
4.99
iCite
Revised in PubMed
2026-01-28
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Fleming GFGini F
2Sill MWMichael W
3Darcy KMKathleen M
4McMeekin DSD Scott
5Thigpen JTJ Tate
6Adler LMLisa M
7Berek JSJonathan S
8Chapman JAJulia A
9DiSilvestro PAPaul A
10Horowitz IRIra R
11Fiorica JVJames V

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibodies, MonoclonalMajor topic
Antineoplastic AgentsMajor topic
Endometrial NeoplasmsMajor topic
Erb-b2 Receptor Tyrosine KinasesMajor topic
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized
Female
Gene Amplification
Humans
Immunohistochemistry
Middle Aged
Neoplasm Recurrence, Local
Trastuzumab

Source PubMed

Download CSV of topics

Grants5

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
U10 CA027469NCI NIH HHSUnited StatesR10CA027469PubMed and NIHNIH RePORTER
U10 CA037517NCI NIH HHSUnited StatesU10CA037517PubMed and NIHNIH RePORTER
CA 37517NCI NIH HHSUnited StatesU10CA037517PubMed and NIHNIH RePORTER
CA 27469NCI NIH HHSUnited StatesR10CA027469PubMed and NIHNIH RePORTER
U10CA027469NIHNIH RePORTER

Download CSV of grants

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in20172595
Letter to the Editor referring to the manuscript entitled: "Phase II trial of trastuzumab in women with advanced or recurrent HER-positive endometrial carcinoma: a Gynecologic Oncology Group study" recently reported by Fleming et al., (Gynecol Oncol., 116;15-20;2010).
https://conductscience.org/library/papers/20172595

Source PubMed

Download CSV of comments and corrections

References20

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
18622019Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.J Clin Oncol1996https://conductscience.org/library/papers/8622019PubMed
216683005Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.Nat Clin Pract Oncol2006https://conductscience.org/library/papers/16683005PubMed
39280033Bayesian interim analysis of phase II cancer clinical trials.Stat Med1997https://conductscience.org/library/papers/9280033PubMed
416803532Use of trastuzumab in the treatment of metastatic endometrial cancer.Int J Gynecol Cancer2006https://conductscience.org/library/papers/16803532PubMed
59819829Optimal flexible designs in phase II clinical trials.Stat Med1998https://conductscience.org/library/papers/9819829PubMed
616322209High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma.Cancer Res2005https://conductscience.org/library/papers/16322209PubMed
718316611Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells.Cancer Res2008https://conductscience.org/library/papers/18316611PubMed
817945336An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study.Gynecol Oncol2008https://conductscience.org/library/papers/17945336PubMed
917611206Trastuzumab--mechanism of action and use in clinical practice.N Engl J Med2007https://conductscience.org/library/papers/17611206PubMed
1018221484Mutual exclusiveness between PIK3CA and KRAS mutations in endometrial carcinoma.Int J Gynecol Cancer2008https://conductscience.org/library/papers/18221484PubMed
1116710036HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients.J Clin Oncol2006https://conductscience.org/library/papers/16710036PubMed
1218555254Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu.Int J Gynaecol Obstet2008https://conductscience.org/library/papers/18555254PubMed
1316166416Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer.Clin Cancer Res2005https://conductscience.org/library/papers/16166416PubMed
1417908983Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency.Clin Cancer Res2007https://conductscience.org/library/papers/17908983PubMed
1514752523
Analysis of HER-2/neu amplification in endometrial carcinoma by chromogenic in situ hybridization. Correlation with fluorescence in situ hybridization, HER-2/neu, p53 and Ki-67 protein expression, and outcome.
Mod Pathol2004https://conductscience.org/library/papers/14752523PubMed
1617009989HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications.Int J Gynecol Cancer2006https://conductscience.org/library/papers/17009989PubMed
1716328593Antibody-based targeted therapy for gastric cancer.Gastric Cancer2005https://conductscience.org/library/papers/16328593PubMed
1810561337
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.
J Clin Oncol1999https://conductscience.org/library/papers/10561337PubMed
1918508484Her2 cross talk and therapeutic resistance in breast cancer.Front Biosci2008https://conductscience.org/library/papers/18508484PubMed
2015894362Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization.Gynecol Oncol2005https://conductscience.org/library/papers/15894362PubMed

Download CSV of references

Cited by102

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 213 citations.

PMIDTitleJournalYearIn PapersSource
42630891Natural killer cells at the interface of tumor immune escape and immunotherapy resistance in endometrial cancer.Front Immunol2026https://conductscience.org/library/papers/42630891PubMed
42449635Systemic Treatment Strategies Beyond Chemotherapy in Recurrent or Advanced Endometrial Cancer: A Systematic Review and Meta-Analysis.Cancers (Basel)2026https://conductscience.org/library/papers/42449635PubMed
41892160Molecular Profiling and Treatment Outcomes in Uterine Serous Carcinoma: Prognostic Role of Estrogen Receptor Expression.Curr Oncol2026https://conductscience.org/library/papers/41892160PubMed
41568388Human epidermal growth factor receptor 2 expression in gynecologic serous carcinomas and preliminary analysis of its characteristics in patients post-neoadjuvant chemotherapy.Front Oncol2025https://conductscience.org/library/papers/41568388PubMed
41496508ERBB2 amplification is a late event in the pathogenesis of high-grade endometrial carcinomas with heterogeneous HER2 expression.J Pathol2026https://conductscience.org/library/papers/41496508PubMed
41306899Genomics of uterine malignancies and the potential of precision medicine.Ther Adv Med Oncol2025https://conductscience.org/library/papers/41306899PubMed
41294658Exceptional Response to Trastuzumab Deruxtecan (T-DXd) in HER2-Positive Metastatic Endometrial Cancer.Curr Oncol2025https://conductscience.org/library/papers/41294658PubMed
41270342AXL inhibition improves the therapeutic efficacy of trastuzumab in high-risk endometrial cancer.Gynecol Oncol2026https://conductscience.org/library/papers/41270342PubMed
41211166Bispecific antibodies in the treatment of epithelial ovarian, endometrial, and cervical cancer: an overview of current applications, challenges, and emerging opportunities.Explor Target Antitumor Ther2025https://conductscience.org/library/papers/41211166PubMed
40862761HER2/neu as a Signaling and Therapeutic Marker in Uterine Serous Carcinoma.Cells2025https://conductscience.org/library/papers/40862761PubMed
40195456HER2 testing: evolution and update for a companion diagnostic assay.Nat Rev Clin Oncol2025https://conductscience.org/library/papers/40195456PubMed
40056788Updates and controversies in the management of uterine serous carcinoma and uterine carcinosarcoma.Int J Gynecol Cancer2025https://conductscience.org/library/papers/40056788PubMed
39118940Narrative review on the evolving role of HER2/neu targeting in uterine serous cancers.Ann Transl Med2024https://conductscience.org/library/papers/39118940PubMed
38658487High-Grade Endometrial Cancer: Molecular Subtypes, Current Challenges, and Treatment Options.Reprod Sci2024https://conductscience.org/library/papers/38658487PubMed
38262242A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2).Gynecol Oncol2024https://conductscience.org/library/papers/38262242PubMed
38256137Molecular Targeting of the Human Epidermal Growth Factor Receptor-2 (HER2) Genes across Various Cancers.Int J Mol Sci2024https://conductscience.org/library/papers/38256137PubMed
37956617High-fat diet and obesity are associated with differential angiogenic gene expression in epithelial ovarian cancer.Gynecol Oncol2023https://conductscience.org/library/papers/37956617PubMed
37558129HER2 Genetic Intratumor Heterogeneity Is Associated With Resistance to Trastuzumab and Trastuzumab Emtansine Therapy in Recurrent High-Grade Endometrial Cancer.Mod Pathol2023https://conductscience.org/library/papers/37558129PubMed
37368179New insights for gynecological cancer therapies: from molecular mechanisms and clinical evidence to future directions.Cancer Metastasis Rev2023https://conductscience.org/library/papers/37368179PubMed
37345001HER2 Intratumoral Heterogeneity in Breast Cancer, an Evolving Concept.Cancers (Basel)2023https://conductscience.org/library/papers/37345001PubMed

See all 102 cited byDownload CSV of cited by

Genes10

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/19840887

GET https://conductscience.org/api/papers/v1/19840887/cited_by?page=2